Regulatory Affairs Test
Here you can take take a self competency review test on Drug Regulatory Affairs. Regulatory Affairs review test is mcq type assessment test where you can check your regulatory skills.... Read More
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
Recent updates
Case Insight – Torrent Pharma to acquire dermatology company Curatio Health Care
Posted on28 Sep 2022
TagsTorrent, torrent pharma acquisition, torrent pharma derma, torrent pharma's entry into derma business
Comments0
Torrent Pharmaceuticals Ltd will acquire dermatology company Curatio Health Care India Pvt Ltd for ₹2,000 crore. The consideration includes ₹115 crore (on the date of signing) of cash and cash equivalents... Read More
Pfizer to acquire Biohaven Pharma for $11.6 billion
Posted on11 May 2022
Comments0
Pfizer entered into a definitive agreement under which Pfizer will acquire Biohaven for 11.6 billion $. Biohen is the maker of Nurtec ODT, an innovative dual-acting migraine therapy approved for... Read More
Aurobindo Pharma acquires Veritaz Healthcare
Aurobindo Pharma Ltd has announced the acquisition of the domestic formulation business of Veritaz Healthcare for a consideration of Rs. 171 crore on debt-free cash-free basis. With this acquisition, Aurobindo... Read More
Sun Pharma to launch Vortioxetine in India
Sun Pharma has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version of Vortioxetine in India under the brand name,... Read More
Is HEOR and Market Access is same?
HEOR and market access are the two separate domain or functional area within pharmaceutical organization. But they work for the same or similar objective. Both are having objective to gain... Read More
Case Study : US FDA approval of Marinus Pharma’s Ztalmy
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the US Food and Drug Administration (FDA) has approved Ztalmy (ganaxolone)... Read More
Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China
Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China. Under the terms of the agreement, Lynk Pharmaceuticals... Read More
What if Design of experiments (DoE) approach?
Posted on21 Mar 2022
Comments0
Design of experiments (DoE) is a systematic approach aiming to maximize information content from an experimental study, while keeping the number of experiments low. During formulation development, DoE is used... Read More
Torrent Pharma to manufacture and sell Pfizer’s Paxlovid generic
Torrent Pharmaceuticals Limited (TPL) has announced that it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with... Read More
Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative
AstraZeneca launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex diseases. AstraZeneca launches this initiative at EXPO 2020... Read More
Case Study: Pfizer’s Arena acquisition – A $6.7B deal
Pfizer will acquire Arena Pharmaceuticals for $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. Why Pfizer acquired Arena? The proposed acquisition of Arena complements Pfizer’s capabilities... Read More
Zydus gets orphan drug designation from USFDA for antimalarial compound
Zydus Cadila said its antimalarial compound ZY19489′, which is currently under development with Medicines for Malaria Venture (MMV), has received ‘orphan drug designation’ from the US FDA. The orphan drug... Read More
Keros Therapeutics Strategic deal with Hansoh Pharma for Rights to KER-050 in China
Keros Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need,... Read More
Case Insight: Natco acquires Dash Pharmaceuticals
Posted on17 Dec 2021
Comments0
NATCO Pharma, through its affiliates, is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC subject to satisfactory completion of due diligence, execution of definitive agreements and compliance... Read More
Cadila launches ayurvedic energy tonic Healtherbs
Drug major Cadila Pharmaceuticals has introduced an ayurvedic general health tonic that helps keep the body young, active and fit. The key ingredients of Healtherbs include Gokhru (Tribulus terrestris), Ashwagandha... Read More
Cipla’s social initiative to improve access to nebulisers in primary healthcare centres of rural India
Cipla Limited announced a first-of-its-kind initiative to improve access to nebulization therapy specifically for patients in the rural sections of the country. With Cipla’s unmatched presence across the care continuum... Read More
Aqilion buys rights to Phase-I ready anti-inflammatory program from LEO Pharma
Swedish life science company Aqilion has acquired all rights to Regulus, a Phase I-ready anti-inflammatory program, from Denmark-headquartered dermatology specialist LEO Pharma, which developed the project from early internal discovery... Read More
SPARC entered into a licensing agreement with Biomodifying
Sun Pharma Advanced Research Company (SPARC) has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target. Biomodifying, LLC is a biotech company... Read More
Pharma Case Study: Merck’s $11.5B acquisition of Acceleron
Posted on03 Oct 2021
Comments0
Merck will acquire Acceleron Pharma, Inc. XLRN for $180 per share in cash for an approximate total equity value of $11.5 billion in a bid to build its rare diseases... Read More
Selling Skills for Medical Representatives
InstructorKnowledge Process Enhancer
TypeOnline Course
Price$390
KPE-C-080 Certificate Course in Pharma Business Development & Licensing
InstructorKnowledge Process Enhancer
TypeOnline Course
Price$490
Drug Discovery to Commercialization Pathway
InstructorKnowledge Process Enhancer
TypeOnline Course
Price$180
KPE-C-077 – Fundamental Training on Data Integrity in pharmaceutical and biopharmaceutical industry
InstructorKnowledge Process Enhancer
TypeOnline Course
Price$180
KPE-C-064N KPE’s 1 Month Certificate Course in Pharma Sales Management
InstructorKnowledge Process Enhancer
TypeOnline Course
Price$390
Fundamental Training on Pharma Marketing Plan Development
InstructorKnowledge Process Enhancer
TypeOnline Course
Price$225
Regulatory Affairs Advance Strategic Planning
InstructorKnowledge Process Enhancer
TypeOnline Course
Price$180
